✨ Medicines Consent Notices




NEW ZEALAND GAZETTE, No. 14
9 FEBRUARY 2012


Product: Meropenem Ranbaxy
Active Ingredient: Meropenem trihydrate 1140mg equivalent to Meropenem 1g
Dosage Form: Powder for injection
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer: Ranbaxy Laboratories Limited, Madhya Pradesh, India

Dated this 2nd day of February 2012.

DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go668


Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:

Schedule

Product: Arrow - Ropinirole 0.25
Active Ingredient: Ropinirole hydrochloride 0.285mg equivalent to Ropinirole 0.25mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Arrow Pharmaceuticals (NZ) Limited
Manufacturer: Arrow Laboratories Limited, Croydon, Australia

Product: Arrow - Ropinirole 0.5
Active Ingredient: Ropinirole hydrochloride 0.57mg equivalent to Ropinirole 0.5mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Arrow Pharmaceuticals (NZ) Limited
Manufacturer: Arrow Laboratories Limited, Croydon, Australia

Product: Arrow - Ropinirole 1
Active Ingredient: Ropinirole hydrochloride 1.14mg equivalent to Ropinirole 1mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Arrow Pharmaceuticals (NZ) Limited
Manufacturer: Arrow Laboratories Limited, Croydon, Australia

Product: Arrow - Ropinirole 2
Active Ingredient: Ropinirole hydrochloride 2.28mg equivalent to Ropinirole 2mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Arrow Pharmaceuticals (NZ) Limited
Manufacturer: Arrow Laboratories Limited, Croydon, Australia

Dated this 2nd day of February 2012.

DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go669


Renewal of Provisional Consent to the Distribution of Medicines

Pursuant to section 23 (4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicines set out in the Schedule hereto:

Schedule

Product: Cal.D.Forte
Active Ingredient: Colecalciferol 1.25mg equivalent to 50,000 IU
Dosage Form: Coated tablet
New Zealand Sponsor: PSM Healthcare Limited trading as API Consumer Brands
Manufacturer: PSM Healthcare Limited trading as API Consumer Brands, Auckland, New Zealand

Note: This renewed consent is valid for one year from 12 February 2012.

Product: Clopine
Active Ingredient: Clozapine 25mg
Dosage Form: Tablet
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer: Douglas Manufacturing Limited, Auckland, New Zealand



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2012, No 14





✨ LLM interpretation of page content

πŸ₯ Consent to Distribution of Meropenem Ranbaxy

πŸ₯ Health & Social Welfare
2 February 2012
Medicines, Distribution, Meropenem, Antibiotics, Douglas Pharmaceuticals
  • DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health

πŸ₯ Consent to Distribution of Arrow Ropinirole Medicines

πŸ₯ Health & Social Welfare
2 February 2012
Medicines, Distribution, Ropinirole, Arrow Pharmaceuticals
  • DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health

πŸ₯ Renewal of Provisional Consent for Cal.D.Forte and Clopine

πŸ₯ Health & Social Welfare
2 February 2012
Medicines, Renewal, Cal.D.Forte, Clopine, PSM Healthcare, Douglas Pharmaceuticals
  • DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health